# A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

> **NCT04906434** · PHASE1 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Liver Cancer

## Interventions

- **DRUG:** ABSK-011

## Key facts

- **NCT ID:** NCT04906434
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-26
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906434, "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04906434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*